Point-of-care Xpert® MTB/RIF for smear-negative tuberculosis suspects at a primary care clinic in South Africa

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 3, 2013, Pages 368-372

  Van Rie, A ^a   Page Shipp, L ^b   Hanrahan, C F ^a   Schnippel, K ^b   Dansey, H ^c   Bassett, J ^c   Clouse, K ^a,d   Scott, L ^e   Stevens, W ^e,f   Sanne, I ^b,d  

^a IL   (United States)

^b RIGHT TO CARE   (South Africa)

^c Witkoppen Health and Welfare Centre   (South Africa)

^d Clinical HIV Research Unit   (South Africa)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^f NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

Author keywords

Cost; Diagnosis; PCR

Indexed keywords

RIFAMPICIN;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BIOMICROSCOPY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; COST BENEFIT ANALYSIS; COST CONTROL; DIAGNOSTIC ACCURACY; DIAGNOSTIC KIT; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; INTERMETHOD COMPARISON; MALE; MYCOBACTERIUM TUBERCULOSIS; OUTCOME ASSESSMENT; POINT OF CARE TESTING; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SOUTH AFRICA; SPUTUM SMEAR; TUBERCULOSIS;

ADULT; AMBULATORY CARE; ANTITUBERCULAR AGENTS; BACTERIOLOGICAL TECHNIQUES; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; FEMALE; HEALTH CARE COSTS; HEALTH EXPENDITURES; HUMANS; LOGISTIC MODELS; MALE; MYCOBACTERIUM TUBERCULOSIS; ODDS RATIO; POINT-OF-CARE SYSTEMS; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PRIMARY HEALTH CARE; SOUTH AFRICA; SPUTUM; TIME FACTORS; TUBERCULOSIS, PULMONARY;

EID: 84874028753     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0392     Document Type: Article

References (7)

1. World Health Organization. WHO endorses new rapid tuberculosis test. A major milestone for tuberculosis diagnosis and care. Geneva, Switzerland: WHO, 2010. http://www.who.int/mediacentre/news/releases/2010/tb-test20101208/en/ index.html Accessed November 2012.
2. World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO report 2009. WHO/HTM/TB/2009.411. Geneva, Switzerland: WHO, 2010.
3. Getahun H, Harrington M, O'Brien R, Nunn P. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet 2007; 369: 2042-2049.
4. MacPherson P, Dimairo M, Bandason T, et al. Risk factors for mortality in smear-negative tuberculosis suspects: a cohort study in Harare, Zimbabwe. Int J Tuberc Lung Dis 2011; 15: 1390-1396.
5. World Health Organization. Public-private partnership announces immediate 40 percent cost reduction for rapid TB test. Geneva, Switzerland: WHO, 2012. http://www.who.int/tb/features-archive/GeneXpert-press-release-final.pdf Accessed January 2013.
6. Boehme C C, Nicol M P, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011; 377: 1495-1505.
7. Vassall A, van Kampen S, Sohn H, et al. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high-burden countries: a cost-effectiveness analysis. PLoS Med 2011; 8: e1001120.